Sébastien Delhaye

Sébastien Delhaye

Auto-generated profile, based on publicly available information

Sébastien Delhaye

CNRS, UMR7275, Universite Cote d Azur, Institut de Pharmacologie Moleculaire et Cellulaire, 06560 Valbonne, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
SDSébastien Delhaye
Sébastien Delhaye
Barbara BardoniBarbara Bardoni
Barbara Bardoni
Phosphodiesterases (PDEs) are enzymes involved in the homeostasis of both cAMP and cGMP. They are members of a family of proteins that includes 11 subfamilies with different substrate specificities. Their main function is to catalyze the hydrolysis of cAMP, cGMP, or both. cAMP and cGMP are two key second messengers that modulate a wide array of intracellular processes and neurobehavioral functions, including memory and cognition. Even if these enzymes are present in all tissues, we focused on those PDEs that are expressed in the brain. We took into consideration genetic variants in patients affected by neurodevelopmental disorders, phenotypes of animal models, and pharmacological effects of PDE inhibitors, a class of drugs in rapid evolution and increasing application to brain disorders. Collectively, these data indicate the potential of PDE modulators to treat neurodevelopmental diseases characterized by learning and memory impairment, alteration of behaviors associated with depression, and deficits in social interaction. Indeed, clinical trials are in progress to treat patients with Alzheimer’s disease, schizophrenia, depression, and autism spectrum disorders. Among the most recent results, the application of some PDE inhibitors (PDE2A, PDE3, PDE4/4D, and PDE10A) to treat neurodevelopmental diseases, including autism spectrum disorders and intellectual disability, is a significant advance, since no specific therapies are available for these disorders that have a large prevalence. In addition, to highlight the role of several PDEs in normal and pathological neurodevelopment, we focused here on the deregulation of cAMP and/or cGMP in Down Syndrome, Fragile X Syndrome, Rett Syndrome, and intellectual disability associated with the CC2D1A gene.

23 August 2018 in Cerebral Cortex
Verified
Journal Article
Closed access
PDF file
TMThomas Maurin
Thomas Maurin
FMFrancesca Melancia
Francesca Melancia
MJMarielle Jarjat
Marielle Jarjat
LCLiliana Castro
Liliana Castro
Lara CostaLara Costa
Lara Costa
Barbara BardoniBarbara Bardoni
Barbara Bardoni
The fragile X mental retardation protein (FMRP) is an RNA-binding protein involved in translational regulation of mRNAs that play key roles in synaptic morphology and plasticity. The functional absence of FMRP causes the fragile X syndrome (FXS), the most common form of inherited intellectual disability and the most common monogenic cause of autism. No effective treatment is available for FXS. We recently identified the Phosphodiesterase 2A (Pde2a) mRNA as a prominent target of FMRP. PDE2A enzymatic activity is increased in the brain of Fmr1-KO mice, a recognized model of FXS, leading to decreased levels of cAMP and cGMP. Here, we pharmacologically inhibited PDE2A in Fmr1-KO mice and observed a rescue both of the maturity of dendritic spines and of the exaggerated hippocampal mGluR-dependent long-term depression. Remarkably, PDE2A blockade rescued the social and communicative deficits of both mouse and rat Fmr1-KO animals. Importantly, chronic inhibition of PDE2A in newborn Fmr1-KO mice followed by a washout interval, resulted in the rescue of the altered social behavior observed in adolescent mice. Altogether, these results reveal the key role of PDE2A in the physiopathology of FXS and suggest that its pharmacological inhibition represents a novel therapeutic approach for FXS.

27 September 2018 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
SCSara Castagnola
Sara Castagnola
SDSébastien Delhaye
Sébastien Delhaye
AFAlessandra Folci
Alessandra Folci
APAgnès Paquet
Agnès Paquet
FBFrédéric Brau
Frédéric Brau
TMThomas Maurin
Thomas Maurin
Fragile X syndrome (FXS), the most common form of inherited intellectual disability (ID) and a leading cause of autism, results from the loss of expression of the Fmr1 gene which encodes the RNA-binding protein Fragile X Mental Retardation Protein (FMRP). Among the thousands mRNA targets of FMRP, numerous encode regulators of ion homeostasis. It has also been described that FMRP directly interacts with Ca2+ channels modulating their activity. Collectively these findings suggest that FMRP plays critical roles in Ca2+ homeostasis during nervous system development. We carried out a functional analysis of Ca2+ regulation using a calcium imaging approach in Fmr1-KO cultured neurons and we show that these cells display impaired steady state Ca2+ concentration and an altered entry of Ca2+ after KCl-triggered depolarization. Consistent with these data, we show that the protein product of the Cacna1a gene, the pore-forming subunit of the Cav2.1 channel, is less expressed at the plasma membrane of Fmr1-KO neurons compared to wild-type (WT). Thus, our findings point out the critical role that Cav2.1 plays in the altered Ca2+ flux in Fmr1-KO neurons, impacting Ca2+ homeostasis of these cells. Remarkably, we highlight a new phenotype of cultured Fmr1-KO neurons that can be considered a novel cellular biomarker and is amenable to small molecule screening and identification of new drugs to treat FXS.

1 December 2019 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
MDMalgorzata Drozd
Malgorzata Drozd
SDSébastien Delhaye
Sébastien Delhaye
TMThomas Maurin
Thomas Maurin
SCSara Castagnola
Sara Castagnola
MGMauro Grossi
Mauro Grossi
Barbara BardoniBarbara Bardoni
Barbara Bardoni
Fragile X-associated tremor ataxia syndrome (FXTAS) is a rare disorder associated to the presence of the fragile X premutation, a 55-200 CGG repeat expansion in the 5' UTR of the FMR1 gene. Two main neurological phenotypes have been described in carriers of the CGG premutation: (1) neurodevelopmental disorders characterized by anxiety, attention deficit hyperactivity disorder (ADHD), social deficits, or autism spectrum disorder (ASD); and (2) after 50 years old, the FXTAS phenotype. This neurodegenerative disorder is characterized by ataxia and a form of parkinsonism. The molecular pathology of this disorder is characterized by the presence of elevated levels of Fragile X Mental Retardation 1 (FMR1) mRNA, presence of a repeat-associated non-AUG (RAN) translated peptide, and FMR1 mRNA-containing nuclear inclusions. Whereas in the past FXTAS was mainly considered as a late-onset disorder, some phenotypes of patients and altered learning and memory behavior of a mouse model of FXTAS suggested that this disorder involves neurodevelopment. To better understand the physiopathological role of the increased levels of Fmr1 mRNA during neuronal differentiation, we used a small interfering RNA (siRNA) approach to reduce the abundance of this mRNA in cultured cortical neurons from the FXTAS mouse model. Morphological alterations of neurons were rescued by this approach. This cellular phenotype is associated to differentially expressed proteins that we identified by mass spectrometry analysis. Interestingly, phenotype rescue is also associated to the rescue of the abundance of 29 proteins that are involved in various pathways, which represent putative targets for early therapeutic approaches.

6 April 2026
Verified
Thesis
Closed access
SDSébAstien Delhaye
SébAstien Delhaye
Le Syndrome de l’X Fragile (SXF) est la forme la plus fréquente de déficience intellectuelle héréditaire. Le phénotype des patients SXF est complexe. En effet, ils présentent aussi des traits autistiques, de l’hyperactivité et un déficit de l’attention. Au niveau du cerveau, le phénotype majeur est la présence d’épines dendritiques plus nombreuses, plus longues et plus fines. Ces anomalies morphologiques sont associées à des formes altérées de plasticité synaptique chez le modèle murin de SXF, la souris Fmr1-KO. Le SXF est causé par l’expansion (plus de 200 fois) du triplet nucléotidique CGG dans le 5’UTR du gène Fragile X Mental Retardation 1 (FMR1). L’hyperméthylation de cette région du gène FMR1 et, surtout de son promoteur, induit la suppression de l’expression de FMR1 et donc l’absence de la protéine FMRP codé par ce dernier. Une expansion entre 50 et 200 fois du triplet est considérée comme une prémutation et est associée à deux autres maladies : le syndrome du tremblement-ataxie lié au X Fragile (FXTAS), une maladie neurodégénérative, et l’insuffisance ovarienne liée à la prémutation de l’X Fragile (FXPOI). FMRP se lie à l’ARNm et est impliquée dans la régulation de plusieurs étapes du métabolisme de l’ARN, en particulier dans la modulation de la traduction de plusieurs protéines synaptiques. Aucune thérapie n’est aujourd’hui disponible pour traiter les patients atteints de SXF. J’ai montré que FMRP module l’expression de la Phosphodiesterase 2A (PDE2A) au niveau synaptique. PDE2A est une enzyme impliquée dans la dégradation de l’AMPc et du GMPc, deux seconds messagers qui jouent un rôle critique dans le développement et la différenciation des neurones. Quand FMRP est absente, le niveau et l’activité de PDE2A sont augmentés et, en conséquence, les niveaux d’AMPc et de GMPc sont réduits dans le cortex et l’hippocampe. J’ai montré que le traitement avec un inhibiteur spécifique de la PDE2A, le BAY 60-7550, rétablit les déficits sociaux chez les souris Fmr1-KO jeunes et adolescentes, la morphologie anormale des épines dendritiques et la Long Term Depression mGluR-dépendante exagérée. Afin de valider par une approche génétique que la réduction du niveau (et de l’activité) de la PDE2A pourrait avoir un rôle thérapeutique pour le SXF, j’ai croisé la lignée Pde2a+/- avec les souris Fmr1-KO et analysé le phénotype comportemental, la morphologie neuronale et les voies de signalisation liées à l’AMPc et au GMPc dans l’hippocampe et le cortex des souris générées par ce croisement. En effet, j’ai pu montrer que les animaux Fmr1-KOxPde2a+/- ont un phénotype sociocognitif normal comparé aux les animaux Fmr1-KO et Pde2a+/-. En effet, les souris Pde2a+/- ont un comportement très similaire à celui des animaux Fmr1-KO même si les altérations moléculaires dans le cerveau apparaissent inversées comparées à celles des souris Fmr1-KO. Dans leur ensemble, mes résultats montrent l’importance des voies AMPc et GMPc qui dépendent de PDE2A dans la pathophysiologie de FXS et dans le neurodéveloppement. En effet, j’ai identifié un nouveau modèle de maladies du développement du cerveau dû à la réduction du niveau d’activité de Pde2a+/-. Dans la première partie de mon doctorat, j’ai contribué à l’identification de la morphologie des neurones corticaux obtenus à partir d’un modèle murin de FXTAS.

6 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SDSébastien Delhaye
Sébastien Delhaye
MJMarielle Jarjat
Marielle Jarjat
ABAsma Boulksibat
Asma Boulksibat
CSClara Sanchez
Clara Sanchez
Alessandra TempioAlessandra Tempio
Alessandra Tempio
Barbara BardoniBarbara Bardoni
Barbara Bardoni
Phosphodiesterase 2A (PDE2A) is an enzyme involved in the homeostasis of cAMP and cGMP and is the most highly expressed PDE in human brain regions critical for socio-cognitive behavior. In cortex and hippocampus, PDE2A expression level is upregulated in Fmr1 -KO mice, a model of the Fragile X Syndrome (FXS), the most common form of inherited intellectual disability (ID) and autism spectrum disorder (ASD). Indeed, PDE2A translation is negatively modulated by FMRP, whose functional absence causes FXS. While the pharmacological inhibition of PDE2A has been associated to its pro-cognitive role in normal animals and in models of ID and ASD, homozygous PDE2A mutations have been identified in patients affected by ID, ASD and epilepsy. To clarify this apparent paradox about the role of PDE2A in brain development, we characterized here Pde2a +/− mice (homozygote animals being not viable) at the behavioral, cellular, molecular and electrophysiological levels. Pde2a +/− females display a milder form of the disorder with reduced cognitive performance in adulthood, conversely males show severe socio-cognitive deficits throughout their life. In males, these phenotypes are associated with microglia activation, elevated glutathione levels and increased externalization of GluR1 in CA1, producing reduced mGluR-dependent LTD. Overall, our results reveal molecular targets of the PDE2A-dependent pathway underlying socio-cognitive performance. These results clarify the mechanism of action of pro-cognitive drugs based on PDE2A inactivation, which have been shown to be promising therapeutic approaches for Alzheimer Disease, schizophrenia, FXS as well as other forms of ASD.